Literature DB >> 23756166

Regulatory T cells in cancer: an overview and perspectives on cyclooxygenase-2 and Foxp3 DNA methylation.

Mehmet Sahin1, Emel Sahin, Sadi Koksoy.   

Abstract

Epigenetics has been gaining great attention as a therapeutic target in cancer. The cancer genome usually contains both hyper- and hypo-methylated genes to increase invasion, proliferation and metastasis. These cells not only operate their own growth, but also develop various strategies to escape from immune surveillance, and for this aim, regulatory T (Treg) cells support the cancer-mediated immune suppression. The fate of Treg cells is mainly controlled by DNA methylation within the promoter and intronic regions of Foxp3 gene. Foxp3 transcription factor is involved in the development, differentiation and function of Treg cells. COX-2 is also an epigenetically controlled gene in these processes. This enzyme and its product PGE2 plays essential roles in Treg functionality in cancer. Here, we discuss the effects of DNA methylation on cancer and nTreg cells. We also summarize the mechanisms related with COX-2/PGE2 and Foxp3 on inhibitory function of Treg cells in cancer.
Copyright © 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23756166     DOI: 10.1016/j.humimm.2013.05.009

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  9 in total

1.  Epigenetic modification of the FoxP3 TSDR in HAM/TSP decreases the functional suppression of Tregs.

Authors:  Monique R Anderson; Yoshimi Enose-Akahata; Raya Massoud; Nyater Ngouth; Yuetsu Tanaka; Unsong Oh; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-21       Impact factor: 4.147

2.  Breaking barriers for T cells by targeting the EPHA2/TGF-β/COX-2 axis in pancreatic cancer.

Authors:  Jose R Conejo-Garcia
Journal:  J Clin Invest       Date:  2019-07-29       Impact factor: 14.808

Review 3.  Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management.

Authors:  Guoying Ni; Tianfang Wang; Lin Yang; Yuejian Wang; Xiaosong Liu; Ming Q Wei
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 4.  Epigenetic regulations of inflammatory cyclooxygenase-derived prostanoids: molecular basis and pathophysiological consequences.

Authors:  Hedi Harizi
Journal:  Mediators Inflamm       Date:  2015-04-06       Impact factor: 4.711

Review 5.  A Comparative Approach of Tumor-Associated Inflammation in Mammary Cancer between Humans and Dogs.

Authors:  Maria Isabel Carvalho; Ricardo Silva-Carvalho; Isabel Pires; Justina Prada; Rodolfo Bianchini; Erika Jensen-Jarolim; Felisbina L Queiroga
Journal:  Biomed Res Int       Date:  2016-12-08       Impact factor: 3.411

6.  Epigenetic control of Foxp3 in intratumoral T-cells regulates growth of hepatocellular carcinoma.

Authors:  Qin Liu; Fang Du; Wei Huang; Xiaoyi Ding; Zhongmin Wang; Fuhua Yan; Zhiyuan Wu
Journal:  Aging (Albany NY)       Date:  2019-04-21       Impact factor: 5.682

Review 7.  Molecular markers for breast cancer: prediction on tumor behavior.

Authors:  Bruna Karina Banin Hirata; Julie Massayo Maeda Oda; Roberta Losi Guembarovski; Carolina Batista Ariza; Carlos Eduardo Coral de Oliveira; Maria Angelica Ehara Watanabe
Journal:  Dis Markers       Date:  2014-01-28       Impact factor: 3.434

8.  Hypermethylation of FOXP3 Promoter and Premature Aging of the Immune System in Female Patients with Panic Disorder?

Authors:  Martina Prelog; Deborah Hilligardt; Christian A Schmidt; Grzegorz K Przybylski; Johannes Leierer; Giovanni Almanzar; Nady El Hajj; Klaus-Peter Lesch; Volker Arolt; Peter Zwanzger; Thomas Haaf; Katharina Domschke
Journal:  PLoS One       Date:  2016-06-30       Impact factor: 3.240

Review 9.  Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity.

Authors:  Bing Liu; Liyan Qu; Shigui Yan
Journal:  Cancer Cell Int       Date:  2015-11-05       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.